Last updated on November 2019

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstr m's Macroglobulinemia (WM)


Brief description of study

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff for final analysis.

Clinical Study Identifier: NCT03332173

Find a site near you

Start Over